By: IPP Bureau
Last updated : December 07, 2021 12:59 pm
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The Indian pharmaceutical market (IPM) delivered slower growth of 5.0% in October 2021 than 12.4% in September 2021. The acute therapy segment (up 8.1% yoy) performed relatively better than chronic segment (up 2.3% yoy). The acute therapy segment demonstrated robust performance since March 2021 (average growth at 30% yoy) owing to lower base last year. These are a few highlights of India Ratings and Research (Ind-Ra), report on the IPM.
Post normalisation of the high growth months of April 2021 (up 51.5% yoy) and May 2021 (up 47.8%) led by the Covid-19-led lockdown related lower base last year and higher volume growth, the average IPM growth from June to October 2021 has been healthy (up 12.6% yoy).
The price growth, new product launches growth and volume growth stood at 5.5% yoy, 3.5% yoy and 5.6% yoy, respectively, which led to the overall IPM size of INR1,657 billion in October 2021 (September 2021: INR1,444 billion).
Acute therapy segment continues to report healthy growth compared to Chronic segment
The acute therapy segment reported sales growth of 8.1% yoy in October 2021(September 2021: 17.7% yoy; August 2021: 16.9% yoy), while chronic and sub-chronic therapy segments reported growth of 1.9% yoy (7.4% yoy; 10.8% yoy) and 2.9% yoy (8.9%; 15.3%), respectively. During FY21, the acute therapy segment reported a decline on account of COVID-19 while the chronic therapy segment reported an average growth of 7.0%.
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac (chronic; 13.0% of IPM), anti-infectives (acute; 14.4%), gastro-intestinal (acute; 11.6%), anti-diabetic (chronic; 9.4%) and vitamins (acute; 9.0%).
|
|||||||
Company/Therapy (INR million) |
MAT Oct-21 |
Growth yoy |
% total |
Oct 21 |
Oct 20 |
Oct 19 |
Oct 18 |
Cardiac |
|||||||
Sun* |
22,760 |
6.7 |
10.5 |
2,013 |
1,815 |
1,622 |
1,620 |
Torrent |
15,346 |
6.1 |
7.1 |
1,296 |
1,229 |
1,084 |
1,086 |
Lupin |
15,299 |
11.3 |
7.1 |
1,197 |
1,270 |
1,058 |
974 |
Usv |
10,483 |
7.1 |
4.9 |
912 |
880 |
757 |
720 |
Emcure* |
10,294 |
32.4 |
4.8 |
709 |
790 |
572 |
517 |
Anti-Infecives |
|||||||
Aristo |
22,967 |
37.4 |
9.6 |
2,406 |
1,788 |
1,734 |
1,492 |
Alkem* |
21,622 |
18.4 |
9.1 |
1,950 |
1,839 |
1,800 |
1,842 |
Cipla |
20,804 |
35.1 |
8.7 |
1,652 |
1,858 |
1,295 |
1,313 |
Macleods |
15,933 |
43.4 |
6.7 |
1,678 |
1,188 |
1,113 |
1,123 |
Mankind |
14,674 |
14.6 |
6.2 |
1,421 |
1,218 |
1,288 |
1,210 |
Gastro Intestinal |
|||||||
Abbott* |
20,741 |
27.8 |
10.8 |
1,854 |
1,584 |
1,338 |
1,206 |
Sun* |
16,600 |
18.6 |
8.7 |
1,498 |
1,322 |
1,181 |
1,127 |
Alkem* |
10,613 |
16.0 |
5.5 |
910 |
883 |
722 |
717 |
Aristo |
9,492 |
30.2 |
5.0 |
824 |
726 |
554 |
480 |
Dr. Reddys |
9,163 |
19.2 |
4.8 |
732 |
718 |
620 |
575 |
Anti Diabetic |
|||||||
Abbott* |
19,330 |
9.3 |
12.4 |
1,601 |
1,585 |
1,506 |
1,433 |
Usv |
14,802 |
2.3 |
9.5 |
1,204 |
1,263 |
1,172 |
1,162 |
Lupin |
13,873 |
3.0 |
8.9 |
1,045 |
1,218 |
1,064 |
927 |
Sun* |
11,457 |
1.2 |
7.3 |
1,006 |
989 |
919 |
864 |
Sanofi India |
10,588 |
7.0 |
6.8 |
866 |
816 |
741 |
774 |
Vitamins/Minerals/Nutrients |
|||||||
Abbott* |
11,791 |
15.0 |
7.9 |
877 |
1,047 |
727 |
723 |
Mankind |
9,361 |
13.7 |
6.3 |
812 |
817 |
690 |
682 |
Alkem* |
8,458 |
21.3 |
5.7 |
677 |
783 |
524 |
535 |
Torrent |
6,657 |
16.3 |
4.5 |
577 |
531 |
455 |
455 |
Apex |
6,411 |
68.0 |
4.3 |
371 |
548 |
226 |
237 |
Source: AIOCD-AWACS, Ind-Ra |
|
|||||||
Therapy/group names (INR million) |
MAT Oct-21 |
Growth yoy |
% total |
Oct 21 |
Oct 20 |
Oct 19 |
Oct 18 |
Cardiac |
2,15,871 |
10.0 |
100.0 |
17,605 |
17,807 |
14,890 |
13,899 |
Statins |
21,109 |
5.4 |
9.8 |
1,798 |
1,734 |
1,548 |
1,439 |
Angiotensin Ii Antagonists + Diuretics |
15,956 |
-1.4 |
7.4 |
1,269 |
1,380 |
1,233 |
1,200 |
Beta-Blocking Agents, Plain |
15,933 |
8.2 |
7.4 |
1,362 |
1,307 |
1,159 |
1,106 |
Platelet Aggregation Inhibitors |
15,855 |
10.9 |
7.3 |
1,400 |
1,283 |
1,097 |
1,051 |
Angiotensin-Ii Antagonists, Plain |
15,210 |
-1.9 |
7.0 |
1,181 |
1,339 |
1,199 |
1,124 |
Anti-Infectives |
2,38,223 |
26.6 |
100.0 |
20,619 |
19,575 |
18,283 |
17,768 |
Cephalosporins |
76,750 |
23.3 |
32.2 |
7,909 |
6,072 |
6,868 |
6,649 |
Broad Spectrum Penicillins |
30,048 |
10.9 |
12.6 |
3,011 |
2,336 |
2,731 |
2,600 |
Antivirals, Excluding Hiv Products |
24,717 |
59.5 |
10.4 |
909 |
2,415 |
864 |
1,112 |
Macrolides and Similar Types |
21,154 |
20.5 |
8.9 |
1,859 |
1,786 |
1,638 |
1,525 |
Systemic Agents for Fungal Infections |
18,361 |
16.9 |
7.7 |
1,478 |
1,549 |
1,629 |
1,491 |
Gastro Intestinal |
1,91,757 |
20.7 |
100.0 |
16,571 |
15,098 |
13,218 |
12,726 |
Gastroprokinetics |
41,993 |
17.8 |
21.9 |
3,658 |
3,475 |
2,954 |
2,838 |
Anti-Ulcerants Acid Pump Inhibitors |
23,472 |
16.5 |
12.2 |
2,073 |
1,888 |
1,740 |
1,607 |
Antidiarrhoeal Micro-Organisms |
12,869 |
32.7 |
6.7 |
1,081 |
846 |
862 |
767 |
Intestinal Anti-Infective Antidiarrhoeals |
11,722 |
16.4 |
6.1 |
875 |
844 |
835 |
793 |
Hepatic Protectors, Lipotropics |
10,189 |
20.1 |
5.3 |
869 |
879 |
697 |
656 |
Anti Diabetic |
1,56,204 |
6.5 |
100.0 |
13,027 |
12,874 |
11,731 |
10,971 |
Oral Antidiabetics |
1,21,290 |
6.0 |
77.6 |
10,225 |
10,050 |
9,094 |
8,476 |
Human Insulin Premix |
10,572 |
3.4 |
6.8 |
845 |
887 |
883 |
838 |
Insulin Analogues Basal |
8,895 |
10.9 |
5.7 |
711 |
685 |
604 |
613 |
Insulin Analogues Premix |
4,298 |
2.3 |
2.8 |
332 |
367 |
361 |
354 |
Insulin Analogues Rapid |
3,479 |
17.1 |
2.2 |
289 |
268 |
232 |
217 |
Vitamins/Minerals/Nutrients |
1,49,514 |
17.5 |
100.0 |
12,268 |
12,737 |
10,368 |
10,111 |
Traditional Antioxidants (Multivit/Multimineral) |
26,006 |
32.3 |
17.4 |
2,022 |
2,264 |
1,521 |
1,520 |
Calcium Products |
24,742 |
8.1 |
16.5 |
2,175 |
2,095 |
1,957 |
1,938 |
Other Vitamins |
22,724 |
24.1 |
15.2 |
1,767 |
1,985 |
1,403 |
1,356 |
B Complex |
15,089 |
11.0 |
10.1 |
1,195 |
1,309 |
1,119 |
1,062 |
Protein Supplements |
10,261 |
22.4 |
6.9 |
828 |
839 |
642 |
623 |
Source: AIOCD-AWACS, Ind-Ra |